Current treatment strategies for newly diagnosed and relapsed APL
Current treatment strategies for newly diagnosed and relapsed APL
复制标题
新诊断和复发 APL 的当前治疗策略
DOI：
10.11406/rinketsu.58.1872
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Emi N
中科院分区：
文献类型：
--
作者：
Ueda K;Ikeda K;Ikezoe T;Ogawa K;Hashimoto Y;Harada-Shirado K;Ohkawara H;Komatsu N;Shide K;Shimoda K;Koide S;Oshima M;Iwama A and Takeishi Y.;Emi N
急性早幼粒细胞白血病（APL）由其特征性形态（AML FAB M3/M3 v）、特异性染色体易位t（15; 17）和分子相关物（PML/RARα）定义。全反式维甲酸（ATRA）联合化疗治疗治愈率高。三氧化二砷（ATO）的临床试验证实了ATO对复发APL患者的疗效。最近，ATRA和ATO治疗已被证明导致高CR率为大多数新诊断的APL患者。已经进行了许多试验来确定ATRA与ATO组合的最佳方案。
Acute promyelocytic leukemia (APL) is defined by its characteristic morphology (AML FAB M3/M3v), specific chromosomal translocation t (15; 17), and molecular correlates (PML/RARα). Treatment with all-trans retinoic acid (ATRA) combined with chemotherapy has a high cure rate. Clinical trials with arsenic trioxide (ATO) confirmed the efficacy of ATO for patients with relapsed APL. Recently, treatment with ATRA and ATO has been shown to result in high CR rates for the majority of patients with newly diagnosed APL. Many trials have been conducted to determine the optimal schedule for ATRA in combination with ATO.